- Home
- OPTN vs IMRX Comparison
OPTN vs IMRX Comparison
Compare OPTN & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- IMRX
- Stock Information
- Founded
- OPTN 2010
- IMRX 2008
- Country
- OPTN United States
- IMRX United States
- Employees
- OPTN N/A
- IMRX N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- OPTN Health Care
- IMRX Health Care
- Exchange
- OPTN Nasdaq
- IMRX Nasdaq
- Market Cap
- OPTN 78.4M
- IMRX 73.2M
- IPO Year
- OPTN 2017
- IMRX 2021
- Fundamental
- Price
- OPTN $0.45
- IMRX $1.76
- Analyst Decision
- OPTN Strong Buy
- IMRX Buy
- Analyst Count
- OPTN 3
- IMRX 7
- Target Price
- OPTN $3.00
- IMRX $12.80
- AVG Volume (30 Days)
- OPTN 1.2M
- IMRX 801.9K
- Earning Date
- OPTN 11-12-2024
- IMRX 11-13-2024
- Dividend Yield
- OPTN N/A
- IMRX N/A
- EPS Growth
- OPTN N/A
- IMRX N/A
- EPS
- OPTN N/A
- IMRX N/A
- Revenue
- OPTN $75,672,000.00
- IMRX N/A
- Revenue This Year
- OPTN $13.42
- IMRX N/A
- Revenue Next Year
- OPTN $52.99
- IMRX N/A
- P/E Ratio
- OPTN N/A
- IMRX N/A
- Revenue Growth
- OPTN 5.13
- IMRX N/A
- 52 Week Low
- OPTN $0.32
- IMRX $1.00
- 52 Week High
- OPTN $2.10
- IMRX $8.07
- Technical
- Relative Strength Index (RSI)
- OPTN 39.55
- IMRX 37.40
- Support Level
- OPTN $0.42
- IMRX $1.52
- Resistance Level
- OPTN $0.57
- IMRX $1.93
- Average True Range (ATR)
- OPTN 0.05
- IMRX 0.19
- MACD
- OPTN 0.00
- IMRX -0.05
- Stochastic Oscillator
- OPTN 26.39
- IMRX 21.95
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.